Loading…
← CockpitCompetitor Analysis › UTHR United Therapeutics CorporationOpen in the cockpit ↗

United Therapeutics CorporationUTHRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech focused on pulmonary hypertension drugs, also developing gene-edited pig organs for human transplantation.

Momentum strong 73
Mkt cap
$24.6B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$307M
20-day average traded
Fwd P/E
23.9×
forward earnings
ROIC−WACC
+18.6 pp
WACC 7.5%
Hurdle
-16 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$577.34
1D-1.2%
1W-3.1%
1M+4.2%
3M+10.8%
6M+2.4%
YTD+18.5%
1Y+22.3%
ATR %3.1%
Beta0.41
52w lowhigh6.0% off high

What United Therapeutics does

Biotech focused on pulmonary hypertension drugs, also developing gene-edited pig organs for human transplantation.

Earns most of its revenue from drugs built on one molecule, treprostinil, given by inhaler, pill or infusion for pulmonary arterial hypertension (high blood pressure in the lung arteries). The organ work, run through its subsidiary Revivicor, is funded from those drug sales and has no product revenue yet. It is organised as a public benefit corporation.

Products and services

  • Tyvaso (inhaled PAH treatment)
  • Orenitram/Remodulin (PAH treatments)
  • Xenotransplantation program (gene-edited pig organs)

Customers

  • Pulmonologists/cardiologists treating pulmonary hy
  • Transplant centers (future, xenotransplant)

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Pulmonary disease drug development and…

What could go right

  • Tyvaso franchise growth (DPI formulation)
  • Xenotransplantation breakthrough potential

What could go wrong

  • Patent cliff risk on core PAH drugs
  • Binary/long-horizon xenotransplant program risk

Moat: narrow (IP / patents, regulatory licence). Established leadership in a niche rare-disease category (PAH) with patent-protected drug formulations.

Headquarters: Silver Spring, Maryland, US · Founded: 1996 · Employees: 1,400

Named competitors

United Therapeutics at a glance

Size United Therapeutics (UTHR) is a United States Health Care company (Biotechnology) with a market value of $24.6B, the 429th largest of 3,085 United States companies the cockpit tracks. Shares closed at $577.34 on 18 Nov 2026.

Performance Over six months the shares gained 2.4%, against +31.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +20.8%); the operating margin is 43.6% (peer median 24.6%).

Valuation It trades at 23.9× forward earnings against a peer median of 27.7× (8th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.6 points above its cost of capital (7.5% WACC).

Short interest Short interest is 4.3% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 130UTHR 102
Six months, rebased to 100: United Therapeutics against the median of its 20 peers (local-currency closes).

United Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.19B$3.18B$2.88B$2.33B$1.94B
Revenue growth—+11%+24%+20%—
Gross profit$2.75B$2.80B$2.57B$2.07B$1.78B
EBITDA$1.48B$1.60B$1.45B$1.24B$1.04B
Net income$1.23B$1.33B$1.20B$985M$727M
Free cash flow$864M$1.04B$1.08B$748M$656M
Capital expenditure$562M$526M$246M$230M$139M
Total debt$0$0$300M$700M$800M

Quarterly statements and history in the cockpit →

United Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%2269BNTXGMAB068270NBIXBBIONTRAIQVELAN2079401093BMRNTECHLONNHALOKYMR002422CSLKRYSUTHR6-month return →1-month return →
Up and to the right = strong over both horizons. United Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%10×20×30×40×2269GMAB068270NBIXIQVELAN2079401093BMRNTECHLONNHALOARGX002422CSLKRYSUTHRRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. United Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%2269GMAB068270NBIXIQVELAN1093TECHHALOARGXUTHRGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. United Therapeutics is the large dot.

United Therapeutics competitors and peer comparison

Head to head with its named competitors (UTHR vs JNJ vs MRK vs LQDA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
United Therapeutics UTHR$24.6B+2%+2%44%23.9×0.3%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Liquidia LQDA$5.08B-9%+798%47%13.8×5.0%

How United Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

United Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureUTHRPeer medianRank in peer set
1-month return+4.2%+0.9%10th highest of 21
6-month return+2.4%+31.4%3rd lowest of 21
Distance from 52-week high-6.0%-14.3%5th highest of 21
Revenue growth (TTM)+1.9%+20.8%7th lowest of 21
Operating margin43.6%24.6%3rd highest of 21
Forward P/E23.9×27.7×8th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.3%11.1%4th least demanding of 17
Growth delivered (Del g)+16.5%+14.8%9th highest of 17
Hurdle (Req g minus delivered)-16.2 pp-7.5 pp5th least demanding of 17
ROIC minus cost of capital+18.6 pp+1.3 pp5th highest of 21
EV / EBITDA15.2×16.7×4th cheapest of 16
Net debt / EBITDA-1.4×1.2×4th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%

Questions

Who are United Therapeutics's main competitors?
Named competitors: Johnson & Johnson (Actelion) (JNJ), Merck & Co. (MRK), Liquidia Corporation (LQDA). The cockpit's measured peer set (industry) also includes Wuxi Bio (2269.HK), BioNTech SE Sponsored ADR (BNTX), Genmab A/S (GMAB.CO), Celltrion (068270.KS), Neurocrine Biosciences (NBIX), BridgeBio Pharma (BBIO).
Is United Therapeutics expensive compared with its peers?
On forward p/e it trades at 23.9× against a peer median of 27.7×, 8th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has United Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +2.4% against +31.4% for the median peer; over one year +22.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.